Milind Desai MD MBA

Vice Chair, Dir Hcm Ctr, Med Dir Aortic Ctr, HVTI, DirClinOps , CVM, Haslam Chair, Prof of Med, Cleveland Clinic. Visiting Prof, Univ Oxford, UK, views mine

[HFAPresident @HFA_President]

🫀How should we diagnose & manage #HCM?

This #EJHF expert consensus statement addresses the gray zones clinicians face in daily practice including:
📍Cardiac myosin inhibitors (#mavacamten, #aficamten) are now central to oHCM care
📍 SCD risk uses a hybrid model: ESC 5-year calculator as the starting point (ICD recommended if ≥6%, not if <4%), with LGE >15%, apical aneurysm or sarcomeric variants tipping borderline (4 to 6%) cases toward implantation
📍Septal reduction therapy works best at high-volume centres
📍Tailored management for pregnancy, #AFib, hypertension & paediatric HCM
📍Future directions: gene therapy, AI-ECG & novel biomarkers

Read more in #EJHF @EJHFEiC :
https://t.co/TeARufGqmT

@escardio @DesaiMilindY @dr_pavia @MarcoMetra @EJHFEiC @UniHeidelberg

[Shada Jadam @ShadaJadamMD]

🫀Honored to present at the ACC Women in Cardiology Midwest Conference and connect with so many incredible women in the field!
Grateful to receive Best Abstract Award in the Resident Category. #ACCWIC @ACCinTouch

@DesaiMilindY @CleClinicHVTI @CCF_IMCHIEFS

[Tenaya Therapeutics @TenayaThera]

Today, we reported promising new interim safety and efficacy data from the on-going clinical trial of TN-201, including encouraging results related to patients’ symptoms, functional capacity &amp; measures of cardiac hypertrophy. Learn more: https://t.co/tEU1Fj0Cwk

[Stuti Shah @stuti0104]

Happy to share our review article on valvular heart disease in pregnancy, now published in Current Obstetrics and Gynecology Reports.

https://t.co/xTO8hbtJFo

[Stuti Shah @stuti0104]

We review current evidence surrounding risk stratification, lesion-specific strategies, anticoagulation considerations, and multidisciplinary cardio-obstetric care in this high-risk population.
Thankful to all my co-authors, especially my mentor @DesaiMilindY for their support!

[Milind Desai MD MBA @DesaiMilindY]

Optimizing Imaging Techniques in Hypertrophic Cardiomyopathy: Challenges and Opportunities https://t.co/aLIutJqO2V @SusanKeenMD @hcmsociety

[Shada Jadam @ShadaJadamMD]

Always grateful for the support of my mentor @DesaiMilindY and our amazing team! @CleClinicHVTI @CCF_IMCHIEFS

[Shada Jadam @ShadaJadamMD]

In 3,546 patients with obstructive HCM undergoing surgical myectomy at the Cleveland Clinic, earlier referral before advanced symptom progression was associated with more favorable long-term outcomes.

[Shada Jadam @ShadaJadamMD]

🫀Happy to share our work on Long-term outcomes of oHCM undergoing surgical myectomy: Impact of symptom severity at presentation

This study represents the largest published single-center surgical myectomy experience to date.

https://t.co/iQqmYukfZb

[Dr. Purvi Parwani @purviparwani]

Landmark #whyCMR paper on HCM
From @JAMA_current

Among patients with #hypertrophic #cardiomyopathy followed for nearly 7 years, key predictors of adverse outcomes included

1. late gadolinium enhancement (LGE) percentage on #whyCMR,
2. left ventricular (LV) mass index,
3. LV end-systolic volume index,
4. history of heart failure, and
5. log(N-terminal pro–B-type natriuretic peptide [NT-proBNP]).

LGE ≥9% of LV mass was associated with substantially increased risk for the composite of hypertrophic cardiomyopathy–related deaths, ventricular arrhythmias, and transplant or LV assist device implant.

These findings provide prospective evidence for integrating #whyCMR and blood biomarkers in risk assessment for hypertrophic cardiomyopathy. #HCM

https://t.co/idxjF1VGV7

Congratulations Dr. @ChrisKramerMD and others from HCM registry on this terrific paper.

[Tenaya Therapeutics @TenayaThera]

Over the weekend at the @escardio Heart Failure Congress, @DesaiMilindY presented data that provided a closer look at our optimized immune suppression and monitoring protocol in the MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201. Learn more: https://t.co/vPGUzoHQ44

[Evangelos K. Oikonomou @ekoikonomou]

🚨New in @JACCJournals

Can #CCTA stratify heart failure risk through radiomic phenotyping of epicardial adiposity?

We derived &amp; externally validated a deep radiomic signature of epicardial fat in &gt;70,000 adults.

w/ @Charis_Oxford on behalf of the #ORFAN consortium

🧵👇

[Evangelos K. Oikonomou @ekoikonomou]

12/ Many thanks to all #ORFAN investigators - led by @Charis_Oxford and the #AMIIC team @RDMOxford @UniofOxford + all funders including but not limited to @TheBHF for supporting this work.

@s_e_petersen @attila_oxford @RonBlankstein @DesaiMilindY @marly_van_assen @JCLRodrigues

[Lars Svensson @LarsSvenssonMD]

Understand the special nuances of caring for young adults with heart disease @CleClinicHVTI’s course in Chicago May 15-16.

Complimentary registration for APPs, Residents &amp; Fellows!

Learn more &amp; register @ link: https://t.co/ab7tSsbKOY

[Cleveland Clinic Heart, Vascular & Thoracic @CleClinicHVTI]

Need expert guidance on managing aortic regurgitation?

Our recent podcast from @LarsSvenssonMD &amp; @DesaiMilindY covers valve repair vs. replacement, timing of surgery in asymptomatic patients &amp; a range of other issues in real-world practice.

https://t.co/qbzfBeIVMu

[NEJM @NEJM]

Presented at #ACC26:

In the phase 3 SCOUT-HCM trial, among adolescents with obstructive hypertrophic cardiomyopathy, the cardiac myosin inhibitor mavacamten led to a significantly greater reduction in left ventricular outflow tract obstruction than placebo. Full trial results: https://t.co/R7qJyV6CEA

@ACCinTouch

[Cleveland Clinic Heart, Vascular & Thoracic @CleClinicHVTI]

@DesaiMilindY tells us what he’s looking forward to @ #ACC2026 — including @ljlaffin’s late-breaking presentation today🫀

Don’t forget to stop by &amp; visit @ClevelandClinic @ booth #1713.

@CCFcards @tavrkapadia #ACC26

[Milind Desai MD MBA @DesaiMilindY]

Mavacamten in Nonobstructive Hypertrophic Cardiomyopathy: Baseline Cha... https://t.co/IWmIm3ARrk

[SagarKalahastiMD @SKalahastiMD]

I just took over as the Program Director of the advanced cardiac imaging fellowship program at the Cleveland Clinic. I’m going to be at ACC 2026 and I will be happy to chat with you about our program! We are currently interviewing for July 2027! Please message me! #ACC26

[Cleveland Clinic Heart, Vascular & Thoracic @CleClinicHVTI]

In this episode of @ClevelandClinic #CardiacConsult, @LarsSvenssonMD &amp; @DesaiMilindY discuss contemporary evaluation &amp; management of aortic valve regurgitation, emphasizing advanced imaging &amp; optimal timing of intervention.

Full podcast: https://t.co/tEdYdd3cSP